Abstract
BackgroundIL-17A blockade is an effective therapy for ankylosing spondylitis (AS) and psoriatic arthritis (PsA), the two prototypical forms of spondyloarthritis (SpA). How IL-17A blockade affects the systemic and local immune...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
